NASDAQ · ERNA
Ernexa Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ERNA: Nov 6, 2026
Ernexa Therapeutics Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-3.84. The reported EPS for the same quarter last year was $-3.75.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-3.84 | $-3.84 | $-3.84 | 1 |
| Dec 2026 | $-4.76 | $-4.76 | $-4.76 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Oct 22, 1:40 PM EDTErnexa Therapeutics Focuses On Clinical Readiness Of Lead Cancer Candidate(RTTNews) – Ernexa Therapeutics (ERNA) announced the release of a new investor video segment highlighting progress advancing ERNA-101, its investigational cell therapy for ovarian cancer, toward first-in-human clinical evaluation.
- RTTNews · Sep 30, 9:40 AM EDTErnexa Therapeutics Advances ERNA-101 Toward Planned Q4 2026 IND(RTTNews) – Ernexa Therapeutics (ERNA) reported positive safety results from three IND-enabling studies of ERNA-101, supporting plans to submit an Investigational New Drug application to the FDA in the fourth quarter of 2026.
- RTTNews · Sep 30, 9:12 AM EDTErnexa Reports Positive ERNA-101 Safety Data Ahead Of Q4 IND(RTTNews) – Wednesday, Ernexa Therapeutics (ERNA) reported positive results from three IND-enabling safety studies of ERNA-101, its investigational iMSC therapy for advanced cancers.
- RTTNews · Sep 29, 11:06 AM EDTErnexa Selected For Emerging Track At 2026 Cell & Gene Meeting On The Mesa(RTTNews) – Tuesday, Ernexa Therapeutics (ERNA) said it has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, where CEO Sanjeev Luther will present the company's oncology strategy and lead candidate ERNA-101.
- RTTNews · Sep 15, 8:53 AM EDTErnexa Reports Positive ERNA-201 Preclinical Data; Advances ERNA-101 Toward Q4 2026 IND(RTTNews) – Ernexa Therapeutics, Inc. (ERNA), a biotechnology company developing engineered cell therapies for advanced cancers, announced positive preliminary preclinical data for ERNA-201, supporting its synthetic induced mesenchymal stem cell (iMSC) platform.
- RTTNews · Aug 29, 6:34 AM EDTWhy Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories(RTTNews) – The Virtual Investor "Why Now" On-Demand Conference, hosted by Virtual Investor Co. in partnership with JTC Team, wrapped up on August 27, 2026. The program is designed to give investors and analysts direct access to management teams, each presenting why now is the ri
- RTTNews · Jun 25, 10:34 PM EDTTop Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS?(RTTNews) – Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which has revised its clinical data readout timeline, among others.
- RTTNews · Jun 17, 9:46 AM EDTErnexa Advances ERNA-101 Toward First-in-Human Study As IND Filing Nears(RTTNews) – Ernexa Therapeutics (ERNA) said it is preparing to transition into a clinical-stage biotechnology company as its lead oncology candidate, ERNA-101, moves toward a planned IND submission in the third quarter of 2026. With manufacturing development completed and GMP pro
- Zacks · May 20, 10:45 AM EDTERNA Stock Shoots Up 140% in a Month: Here's What You Should KnowErnexa Therapeutics stock soars 140% in a month as ERNA-101 shows complete tumor clearance and long-term survival in pre-clinical ovarian cancer models.
- Fintel · May 7, 8:03 PM EDTBrookline Capital Initiates Coverage of Ernexa Therapeutics (ERNA) with Buy RecommendationFintel reports that on May 7, 2026, Brookline Capital initiated coverage of Ernexa Therapeutics (NasdaqCM:ERNA) with a Buy recommendation. What is the Fund Sentiment?
- RTTNews · May 6, 11:53 AM EDTErnexa Reports 100% Survival And Complete Tumor Clearance In Ovarian Cancer Models; Stock Up(RTTNews) – Ernexa Therapeutics (ERNA) unveiled breakthrough preclinical results showing that its lead cell therapy candidate, ERNA-101 achieved complete tumor elimination and 100% long-term survival when combined with PD-1 blockade in syngeneic ovarian cancer models.
- RTTNews · Apr 30, 11:06 AM EDTErnexa Announces 1-for-25 Reverse Stock Split To Maintain Nasdaq Listing; Stock Down(RTTNews) – Share of Ernexa Therapeutics Inc. (ERNA) is down by 20% after the company announced a 1-for-25 reverse stock split of its common stock, effective May 4, 2026.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Ernexa Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.